advertisement
Abstract #5826 Published in IGR 2-1
Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy
Shin DD; Atlas W; Brotherman D; Caine R; Craven R; Gottlieb L; Kolodner H; Kraff C; Kranemann C; Krupin TSurvey of Ophthalmology 2000; 44(Suppl 2):S163-S168
This prospective, multicenter, double-masked, placebo-controlled study evaluated the safety and efficacy of brinzolamide 1% ophthalmic suspension (Azopt) when used adjunctively with open-label timolol maleate 0.5% (Timoptic). One-hundred and thirty-two patients requiring an adjunctive therapy to timolol 0.5% for the treatment of open-angle glaucoma or ocular hypertension were randomized to receive brinzolamide or placebo three times daily (t.i.d.) in addition to timolol 0.5% twice daily (b.i.d.) for three months. Qualifying intraocular pressure (IOP) on timolol 0.5% b.i.d. was 24-36 mmhg in at least one eye at 8:00 A.M. and 21-36 mmhg at 10:00 A.M., with no greater than a 5-mmhg difference between eyes, during two eligibility visits separated by at least seven days. Treatments were compared using a repeated-measures analysis of variance. Adjunctive therapy with brinzolamide resulted in clinically and statistically significant reductions in IOP from the timolol baseline at all visits. IOP changes from a diurnal baseline ranged from -3.3 to -4.1 mmhg for brinzolamide (n=53) compared with -0.9 to -2.5 mmhg for placebo (n=55). Abnormal taste (7.7%) and transient blurred vision (6.2%) were the most frequently reported adverse events. No clinically significant differences in the incidence or severity of ocular signs, visual acuity, cup/disc ratio, or parameters studied on dilated fundus examination were observed between treatment groups. Brinzolamide 1% t.i.d., used adjunctively with timolol 0.5% b.i.d., is safe and well tolerated, and produces clinically and statistically significant additional IOP reductions.
Dr. D.D. Shin, Kresge Eye Institute, Detroit, MI 48201-1423, USA
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
